期刊文献+

晚期卵巢癌新辅助化疗疗效分析及其对预后的影响 被引量:10

Effect and prognostic analysis of applying neoadjuvant chemotherapy in advanced ovarian cancer
下载PDF
导出
摘要 目的探讨术前新辅助化疗在晚期卵巢癌治疗中的疗效及其对预后的影响。方法回顾性分析326例晚期卵巢癌患者,按照直接手术减瘤和新辅助化疗后再减瘤分为两组,比较化疗疗效和预后相关指标。方法新辅助化疗组中,CR+PR87例(58.7%),IP55例(37.2%),SD6例(4.1%)。新辅助化疗组平均术中出血量明显少于术前未化疗组(P<0.05);新辅助化疗组平均手术时间较术前未化疗组缩短,两组比较有显著性差异(P<0.05)。新辅助化疗组满意减瘤率明显高于术前未化疗组(P<0.05)。两组1、3、5年存活率差异无显著性意义(P>0.05)。结论新辅助化疗使晚期卵巢癌手术满意减瘤率提高,但1、3、5年生存率改善不明显。 [ Objective ] To explore the effect and prognostic analysis of neoadjuvant chemotherapy in advanced ovarian cancer. [Methods] 326 patients with advanced ovarian cancer were analyzed retrospectively, and were di- vided into two groups according to whether they had received neoadjuvant chemotherapy or not before operation, the effeet of chemotherapy and prognostic factors were analyzed. [ Results ] 87 patients showed CR and PR, 55 patients showed IP, 6 patients showed SD in neoadjuvant chemotherapy group. The amount of bleeding and time of operation in neoadjuwmt chemotherapy group was significantly less than those of without neoadjuvant chemotherapy group (P 〈 0.05); The optimal cytoreduetive surgery rate in neoadjuvant chemotherapy group was 76.4%. Which was significantly higher than that of without neoadjuvant chemotherapy group (37.6%)(P 〈0.05); There was no significant difference in 1, 3, 5 year survival rates between two groups. [ Conclusion ] Neoadjuvant chemotherapy can improve optimal cytoreducfion surgery rate, but not improve survival rates significantly.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第33期4203-4206,共4页 China Journal of Modern Medicine
关键词 卵巢癌 新辅助化疗 化疗疗效 预后 Ovarian cancer Neoadjuvant chemotherapy Chemotherapy effect Prognostic
  • 相关文献

参考文献14

  • 1BRISTOW RE, TOMACRUZ RS, ARMSTRONG DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum ear: a meta-analysis [J]. J Clin Oncol, 2002, 20(5):1248-1259.
  • 2LEE SJ, KIM BG, LEE JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery[J]. J Obstet Gynaecol Res, 2006, 32(1): 99-106.
  • 3HOU JY, KELLY MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease[J]. Gynecol Oncol, 2007, 105(1): 211-217.
  • 4ZHAO Y, HUANG SS, DU PY. Utilization of paclitaxel combined with cisplatin regimen in the neoadjuvant chemotherapy in locally advanced cervical squamous carcinoma[J]. Journal of Southern Medical University, 2008, 28(11) : 2072-2074.
  • 5INCIURA A, SIMAVICIUS A, JUOZAITYTE E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer:a retrospective study of 574 patients [J]. BMC Cancer, 2006, 8(6): 153.
  • 6EVERETT EN, FRENCH AE, STONE RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage Ⅲ/Ⅳ epithelial ovarian cancer [J]. Am J Obstet Gynecol, 2006, 195 (2): 568-574.
  • 7EVERETT EN, HEUSER CC, PASTORE LM, et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductire surgery for advanced stage epithelial ovarian cancer[J]. Am J Obstet Gynecol, 2005, 193(2): 568-574.
  • 8HOU JY, KELLY MG, YU H, et al. Neoadjuvant chemotherapylessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease[J]. Gynecol Oncol, 2007, 105(1): 211-217.
  • 9BRISTOW RE, CHI DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta analysis[J]. Gynecol Oncol, 2006, 103(3): 1070-1076.
  • 10ONDA T, MATSUMOTO K, SHIBATA T, et al. Phase m trial of up- front debulking surgery versus neoadjuvant chemotherapy for stage Ⅲ/Ⅳ ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602[J]. Jpn J Clin Oncol, 2008, 38(1): 74-77.

同被引文献75

  • 1姚海文,姚彪,林竹.鸦胆子油乳注射液对晚期癌症患者生存质量的影响[J].遵义医学院学报,2008,31(5):503-504. 被引量:3
  • 2李昱川.术前新辅助化疗治疗晚期卵巢癌的疗效分析[J].实用癌症杂志,2014,29(2):220-221. 被引量:14
  • 3谢幸.卵巢癌新辅助化疗[J].中国妇产科临床杂志,2006,7(4):243-244. 被引量:9
  • 4Hou JY,Kelly MG,Yu H. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage Ⅳ disease[J].{H}Gynecologic Oncology,2007,(01):211-217.
  • 5Su EP,West rich GH,Rana AJ. Operative treatment of tibial plateau fractures in patients older than 55 years[J].{H}Clinical Orthopaedics and Related Research,2004,(421):240-248.
  • 6张文璎,薛月珍.晚期卵巢癌肿瘤细胞减灭术术前选择新辅助化疗的评估[J].中国肿瘤临床,2007,34(22):1317-1320. 被引量:2
  • 7Kang S,Kim TJ,Seo SS,et al.Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.Gynecol Oncol,2011,20(1): 18-22.
  • 8Weinberg LE,Rodriguez G,Hurtean JA.The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.J Surg Oncol,2010,104(4) :334-343.
  • 9Freedman OC, Dodge J, Shaw P,et al.Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy.Gynecol Oneol, 2010,119( 1 ) : 22-25.
  • 10Vergote l,Trope CG,Amant F,et al.Neoadjuvant chemotherapy or primary surgery in stage 111 C or 1V ovarian Cancer.N Engl J Med, 2010,363 (10) : 943-953,.

引证文献10

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部